Futibatinib (Lytgobi)

Small molecule

Also known as TAS-120

Approvedregulatory verdict

Evidence outlook

Approved: Cholangiocarcinoma

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Weak signalSingle-arm, accepted for approval (FDA label)

Also in development:Biliary Tract Cancer · Phase 3 · investigational in the US

Also approved (2)
EU
  • Conditional marketing authorisation: monotherapy for adult patients with locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement that have progressed after at least one prior line of systemic therapy (Lytgobi)
Product first approved 2023EMA
JP
  • Treatment of unresectable FGFR2 fusion gene-positive biliary tract cancer that has progressed after cancer chemotherapy
Product first approved 2023PMDA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (5)
Biliary Tract Cancer
NCT07745296 · UNICANCER
2027-01-02 – 2033-07-02 · Biliary Tract Cancer (BTC)
What this study did
NCT07710885 · Taiho Pharmaceutical Co., Ltd.
2026-06-24 – 2031-12-31 · Biliary Tract Cancer
What this study did
Cholangiocarcinoma
NCT04093362 · Taiho Oncology, Inc.
2021-01-06 – 2024-04-22 · Advanced Cholangiocarcinoma, FGFR2 Gene Rearrangements
What this study did
Other / comorbidity
NCT05615818 · UNICANCER
2024-07-18 – 2028-06 · Biliary Tract Neoplasms
What this study did
NCT03784014 · Institut National de la Santé Et de la Recherche Médicale, France
2019-10-19 – 2026-01-20 · Soft Tissue Sarcoma
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT06506955 · Taiho Oncology, Inc.
2024-10-01 – 2027-04-30 · Advanced/Metastatic Cancer
What this study did
Phase 2 (12)
Cholangiocarcinoma
NCT07639528 · Northwestern University
2027-12-10 – 2031-12-10 · Resectable Intrahepatic Cholangiocarcinoma
What this study did
NCT05727176 · Taiho Oncology, Inc.
2023-07-05 – 2026-12 · Advanced Cholangiocarcinoma, FGFR2 Fusions, Gene Rearrangement
What this study did
Other / comorbidity
NCT02693535 · American Society of Clinical Oncology
2016-03-14 – 2028-12-31 · Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
What this study did
NCT06722183 · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
2025-12-16 – 2028-03 · Colorectal Cancer
What this study did
NCT03767075 · Vall d'Hebron Institute of Oncology
2018-12-10 – 2027-11 · Advanced Solid Tumor
What this study did
NCT06263153 · Yuanquan Yang
2024-12-30 – 2027-07-31 · Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
What this study did
NCT05945823 · Taiho Oncology, Inc.
2023-07-13 – 2027-01 · Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer, Siewert Type 1 GEJ Cancer, Pancreatic Cancer
What this study did
NCT04601857 · Taiho Oncology, Inc.
2021-01-07 – 2025-09-16 · Advanced and Metastatic Urothelial Cancer
What this study did
NCT04828486 · Mayo Clinic
2021-08-17 – 2025-08-31 · Advanced Hepatocellular Carcinoma, BCLC Stage A Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
What this study did
NCT05036681 · M.D. Anderson Cancer Center
2021-09-30 – 2025-05-06 · Metastatic Cancer, Endometrium Cancer, Endometrial Carcinoma
What this study did
NCT04189445 · Taiho Oncology, Inc.
2020-08-05 – 2024-11-11 · Advanced or Metastatic Solid Tumor, Advanced or Metastatic Gastric or Gastroesophageal Cancer, Myeloid or Lymphoid Neoplasms (MLN)
What this study did
NCT04024436 · Taiho Oncology, Inc.
2020-01-28 – 2023-09-06 · Metastatic Breast Cancer, FGFR 1 High Amplification, FGFR2 Amplification
What this study did
Phase 1/2 (2)
Cholangiocarcinoma
Other / comorbidity
NCT02813135 · Gustave Roussy, Cancer Campus, Grand Paris
2016-08-03 – 2031-02 · Pediatric Cancer
What this study did
Phase 1 (4)
Biliary Tract Cancer
NCT04999761 · Taiho Pharmaceutical Co., Ltd.
2021-06-01 – 2027-06 · Advanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer, Gastric Cancer, Alveolar Soft Part Sarcoma, Esophageal Cancer, Head and Neck Cancer, Biliary Tract Cancer
What this study did
Other / comorbidity
NCT07594548 · Northwestern University
2026-11-10 – 2031-09-09 · Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Locally Advanced Esophageal Adenocarcinoma, Locally Advanced Gastric Adenocarcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Metastatic Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Esophageal Adenocarcinoma, Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Carcinoma
What this study did
NCT05827614 · Boundless Bio, Inc.
2023-03-24 – 2026-03-17 · Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Carcinoma, High Grade Endometrial Carcinoma, Anogenital Cancer, Head and Neck (HNSCC), Cutaneous Squamous Cell Carcinoma (CSCC), Cervical Squamous Cell Carcinoma, ER+ Breast Cancer, Leiomyosarcoma (LMS), Undifferentiated Pleomorphic Sarcoma (UPS), Pancreatic Cancer Metastatic, Small Cell Lung Cancer
What this study did
NCT04965818 · Taiho Oncology, Inc.
2021-09-20 – 2023-09-21 · Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations, Non-Small Cell Lung Cancer, KRAS Gene Mutation
What this study did

Competitive landscape

This drug's own stage for Biliary Tract Cancer: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Futibatinib (Lytgobi): this drugPhase 3Small moleculeFGFR (FGFR1/2/3/4)not yet gradedNo reviewed efficacy summary in this indication
DurvalumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Reliable signal
NCT04003636: Overall Survival (OS) (Up to approximately 38 months): Arm A: Pembrolizumab + Chemotherapy 12.7 Months (95% CI 11.5 to 13.6) | Arm B: Placebo + Chemotherapy 10.9 Months (95% CI 9.9 to 11.6)
ZanidatamabApprovedMultispecific antibodyHER2Weak signal
NCT04466891: Confirmed ORR 41.3% (95% CI 30.4-52.8); median duration of response 12.9 months (Lancet Oncol 2023)
IvonescimabPhase 3Multispecific antibodyPD-1 + VEGFAnot yet gradedNo reviewed efficacy summary in this indication
Izalontamab BrengitecanPhase 3Antibody–drug conjugateEGFR + HER3not yet gradedNo reviewed efficacy summary in this indication
RilvegostomigPhase 3Multispecific antibodyPD-1 and TIGITnot yet gradedNo reviewed efficacy summary in this indication
Trastuzumab BrengitecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
TovecimigPhase 2/3Multispecific antibodyDLL4 x VEGF-Anot yet gradedNo reviewed efficacy summary in this indication
RamucirumabPhase 2Monoclonal antibodyVEGFR2not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(13 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Futibatinib (Lytgobi) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 2CholangiocarcinomaRecruiting
Est. primary completion 2026-12 · NCT05727176 · CT.gov ↗
What to watch
2027 (6)
April 2027 (1)
Phase 2/3Advanced/Metastatic CancerActive not recruiting
Est. primary completion 2027-04 · NCT06506955 · CT.gov ↗
What to watch
May 2027 (1)
Phase 2Advanced Solid TumorRecruiting
Est. primary completion 2027-05 · NCT03767075 · CT.gov ↗
What to watch
June 2027 (2)
Phase 1Biliary Tract CancerRecruiting
Est. primary completion 2027-06 · NCT04999761 · CT.gov ↗
What to watch
Phase 3Biliary Tract NeoplasmsRecruiting
Est. primary completion 2027-06 · NCT05615818 · CT.gov ↗
What to watch
July 2027 (1)
Phase 2Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8Recruiting
Est. primary completion 2027-07-31 · NCT06263153 · CT.gov ↗
What to watch
December 2027 (1)
Phase 2Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid TumorsRecruiting
Est. primary completion 2027-12-31 · NCT02693535 · CT.gov ↗
What to watch
2028 (1)
March 2028 (1)
Phase 2Colorectal CancerRecruiting
Est. primary completion 2028-03 · NCT06722183 · CT.gov ↗
What to watch
2030 (3)
April 2030 (1)
Phase 3Biliary Tract CancerRecruiting
Est. primary completion 2030-04-30 · NCT07710885 · CT.gov ↗
What to watch
September 2030 (1)
Phase 1Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8 …Recruiting
Est. primary completion 2030-09-09 · NCT07594548 · CT.gov ↗
What to watch
December 2030 (1)
Phase 2CholangiocarcinomaNot yet recruiting
Est. primary completion 2030-12-10 · NCT07639528 · CT.gov ↗
What to watch
2031 (1)
February 2031 (1)
Phase 1/2Pediatric CancerRecruiting
Est. primary completion 2031-02 · NCT02813135 · CT.gov ↗
What to watch
2033 (1)
July 2033 (1)
Phase 3Biliary Tract CancerNot yet recruiting
Est. primary completion 2033-07-02 · NCT07745296 · CT.gov ↗
What to watch

See the full readout calendar ↗